A Dose-Block Randomized, Placebo controlled (Double-blind), Active Controlled(Open-label), Dose-escalation Study to investigate the tolerability, and Pharmacokinetics/Pharmacodynamics of HL2351 after a Single Subcutaneous Administration in Healthy Male Subjects

Trial Profile

A Dose-Block Randomized, Placebo controlled (Double-blind), Active Controlled(Open-label), Dose-escalation Study to investigate the tolerability, and Pharmacokinetics/Pharmacodynamics of HL2351 after a Single Subcutaneous Administration in Healthy Male Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Sep 2016

At a glance

  • Drugs HL 2351 (Primary) ; Anakinra
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Sponsors Handok Inc
  • Most Recent Events

    • 05 Oct 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 01 Jul 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top